Cingulate Inc.

CING

Healthcare|Biotechnology|US

$4.26

+0.02 (+0.47%)

DCF Value

$0.05

Tangible Book / Share

$4.32

Cash / Share

$5.23

Clinical Trials (6)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05631626 Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.	ADHD, ADHD - Combined Type	P3	Completed	26	RCT, Double-blind	CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
NCT05286762 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301	ADHD, Attention Deficit Hyperactivity Disorder	P3	Completed	103	RCT, Double-blind	CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
NCT05924594 Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301	ADHD, ADHD - Combined Type	P3	SUSPENDED	45	RCT, Double-blind	CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
NCT04138498 CTx-1301 Comparative Bioavailability Study	ADHD	P1P2	Completed	45	RCT, Double-blind	Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
NCT04449250 Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects	Healthy Volunteers in Fed and Fasted State	P1	Completed	27	RCT, Open-label	Dexmethylphenidate
NCT07119073 In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)	Healthy Volunteers in Fed and Fasted State	P1	Completed	25	RCT, Open-label	Dexmethylphenidate